| Get Support Donate Get Involved Attend Local Event |
National Hereditary Cancer Week & Previvor Day 2020 September is an important month. We recognize Prostate Cancer Awareness Month and Ovarian Cancer Awareness Month. During National Hereditary Cancer Week (September 27 – October 3) and on National Previvor Day (September 30) we also recognize and honor all those who have been affected by hereditary cancer. We raise awareness so others can have the life-saving information they need to make informed medical decisions. Knowledge is power! We hope you will join us later this month as we recognize these important days.
Read our National Hereditary Cancer Week blog |
Attend Dana-Farber's Lynch Syndrome Virtual Conference on September 12 This virtual, one-day, educational conference is for individuals with Lynch syndrome, their families and caregivers. The program provides attendees with updates on guidelines for screening and prevention, strategies for communicating one’s cancer risk with family, information about the latest advances in treatment and much more. The keynote speaker, Matthias Kloor, PD Dr. med, from Heidelberg University in Germany, will be addressing the latest research on vaccines for Lynch syndrome.
Register today
|
FDA updates breast implant safety info The FDA recently updated its information on breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) and breast implant illness (BII). Visit the advocacy section of the FORCE website to read about the latest information on implant safety and a new video, 7 Key Things You Should Know about Breast Implants. Read more |
Drug combination approved for maintenance therapy for ovarian cancer treatments The FDA has approved the first drug combination to be used as maintenance therapy for ovarian cancer patients who have responded to chemotherapy. Read our XRAY-Behind the Ovarian Cancer Headlines on this exciting approval. #helpnothype
Read our recent XRAY review
|
Volunteer Spotlight: Krystin Morgan and Tammy Fahber Thank you, Krystin and Tammy (FORCE State Impact Leaders in Washington and Peer Navigators) for empowering others to advocate for themselves as they face hereditary cancer decisions and value the incredible friendships that have formed from these relationships over the past eight and five years. We are so incredibly thankful to have you both be a part of our VolunteerFORCE family. If you are interested in paying it forward and making a difference too, please complete a VolunteerFORCE application today.
Read Krystin's and Tammy’s stories
|
Does insulin resistance affect breast cancer survival of Black women? Insulin resistance might be one of the reasons that Black women are more likely than White women to die from breast cancer. Read our XRAY-Behind the Breast Cancer Headlines to find out more. #helpnothype
Read our recent XRAY review
|
Exciting new film/book webinar series Join us for our final webinar book panel discussion and watch recordings of our past events. Hear from others who have faced hereditary cancer decisions and submit questions to our panelists. National Previvor Day, September 30th at 7PM Eastern Time: Beat Breast Cancer Like a Boss Panel Discussion and Book Review with award-winning journalist and seasoned TV producer, Ali Rogin, award-winning songwriter and music producer, Kara DioGuardi, and top-executive and business mogul, Mary Powell Watch the recording: In the Family Documentary Screening and Virtual Cast Reunion with Emmy®-nominated director and producer, Joanna Rudnick Watch the recording: Writing About Your Hereditary Cancer Journey with award-winning memoirists, Mary Ladd and Grace Talusan Register now and/or watch the recordings |
Get virtual support You are not alone! Connect with trained volunteers who understand the decisions you face. Local virtual get-togethers: network in a safe environment Outreach support: connect with your state volunteers Message boards: make new friends and share concerns online Peer Navigation Program: receive personalized support and a resource guide COVID-19 resources: obtain a compiled list to help you and your family |
Navigation portals connect people to information, research and support resources FORCE has new portal pages with links to information, research and support resources. Learn the role that genetics can play in these cancers, treatment options and opportunities to participate in clinical trials. Personalized portals are available for: High-risk women Pancreatic cancer Metastatic prostate cancer Metastatic breast cancer |
Read our FORCE blog for more updates Subscribe to our blog, Thoughts from FORCE, for personal stories and deeper insights into issues that affect our community. Recent topics include: Improving Lives Through Education- By Way of Science Writing Advocacy Through Writing and Research How to Prepare for a Mastectomy Amid COVID and Other Life Events Breaking Breast Cancer Color Barriers and Building Bridges View our blog |
Find HBOC studies and participate in research! Please visit our new and improved HBOC Research Search Tool and Featured Research Page to find and participate in research studies enrolling patients, like you.
Study search tool / Featured research studies |
Clinical trials and research studies need participants The research studies below are enrolling people with, or at high risk for, hereditary cancer. |
Denosumab and mammographic density in premenopausal women with dense breasts This study is looking at the effect of denosumab on breast density of premenopausal women who have dense breasts. Denosumab is an FDA-approved medication for osteoporosis and to prevent fractures in cancer patients with bone metastases. This study could help identify new ways to prevent breast cancer in younger women.
Learn about the study |
Survey on menstruation, menopause and memory The Penn Center for Women's Behavioral Wellness at the University of Pennsylvania wants to learn more about attention and memory in women across the lifespan. We are currently looking for women between the ages of 35-65 to answer questions related to women's heath, cognition, and mood. This survey is open to women at any stage of their menstrual life cycle, including pre-menopausal and post-menopausal women and anything in-between! This survey will take approximately 20 minutes to complete and at the end, you will have the opportunity to register to win a $100 MasterCard gift card. For every 200 people that complete the survey, we will randomly select one person to receive a $100 MasterCard gift card.
Learn more about the study |
Study for people with unexpected genetic results Did you receive an unexpected genetic test result related to cancer risk? A new study is recruiting people who had genetic testing done for some other reason and received results related to their cancer risks. The goal of this study is to learn what people think about, and how they use results like this.
Learn more about the study |
Connect My Variant University of Washington researchers are studying ways to help people with genetic disease risk find and talk to family members that have the same genetic mutations. In this study, researchers will help families connect with each other, talk about genetics, and encourage other relative to get genetic testing. The study team hopes to act as partners to help you find and connect with your relatives. With your help we want to make it easier for people like you to find where familial variants came from and prevent disease in everyone with the same risk variant.
Learn more about the study |
Patients making meaning from education and support materials Individuals with a past or current breast cancer diagnosis are invited to complete a brief survey about documents and materials that make patients feel most supported and help them make meaning from their illness; researchers want to understand how these effects are achieved in order to make recommendations to practitioners, community partners, and others about how best to support patients.
Take the survey |
A study to evaluate rucaparib in patients with solid tumors and with deleterious mutations in HRR genes (LODESTAR) The LODESTAR study is evaluating the response of the PARP inhibitor rucaparib in people with advanced solid tumors (including breast, ovarian, pancreatic, prostate and other cancers) who have an inherited or acquired mutation in any of the following genes: BRCA1, BRCA2, PALB2, RAD51C, RAD51D, BARD1, BRIP1, FANCA, NBN, RAD51 or RAD51B.
Learn more about LODESTAR |
ELLIE's Project Do you have a genetic mutation increasing your risk of cancer? Help inform us how future research on lifestyle habits can better serve YOU! Take a 20-minutes survey to learn about nutrition and exercise in relationship to hereditary cancer mutations.
Take the survey |
IMMray™ PanCan-d Test for early detection of pancreatic cancer in high-risk groups
The Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups is enrolling people who do not have pancreatic cancer, but have a higher risk of developing the disease.
Learn more |
Pilot study of denosumab in BRCA1 or BRCA2 mutation carriers scheduling risk-reducing Salpingo-Oophorectomy Are you a BRCA1 or BRCA2 mutation carrier scheduled to have your fallopian tubes and ovaries removed? Learn about an opportunity to enroll in a clinical trial looking at the effects of denosumab on the ovaries, fallopian tubes, and uterus (for women getting a hysterectomy) of women with a BRCA1 or BRCA2 mutation. Denosumab is an FDA-approved injectable medication that is used to treat osteoporosis and to prevent fractures in cancer patients with bone metastases. The eventual goal is to understand if denosumab may be used to reduce the risk of ovarian cancer in women with a BRCA1 or BRCA2 mutation
Learn more |
GENERATE Study The GENERATE (GENetic Education Risk Assessment and Testing) Study offers genetic testing for people who have a close relative with pancreatic cancer that was caused by a mutation in a gene. Knowing about inherited risk helps families protect themselves against pancreatic and other cancers. Visit the study website to learn more and fill out the Eligibility Questionnaire.
Learn more about GENERATE |
Screening for men at high genetic risk for prostate cancer CALLING ALL MEN WITH A BRCA MUTATION, A LYNCH SYNDROME MUTATION or one of the other mutations listed below! The National Institutes of Health has a clinical trial for men at high genetic risk for prostate cancer. This is trial is for men without prostate cancer, ages 30 to 75, who have tested positive for Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51D, FANCA. The trial involves screening MRI of the prostate every two years and biopsy of the prostate if the MRI is abnormal. There is no cost for travel or study-related tests.
Learn more about the study |
A Study in advanced breast cancer patients with BRCA 1/2 mutations evaluating olaparib alone or in combination with atezolizumab This is a study for women or men who have been diagnosed with advanced breast cancer with a BRCA 1/2 mutation. The goal of this study is to look at whether giving the DNA damage repair inhibitor (PARP inhibitor) olaparib (Lynparza) in combination with the immunotherapy atezolizumab (Tecentriq) improves outcomes for patients compared to olaparib alone.
Learn more about the study |
CheckMate-9KD CheckMate-9KD is a clinical research study for men with metastatic prostate cancer (which means cancer that has spread) that no longer responds to treatments that lower testosterone. Visit the link below to learn more about the study.
Learn more about CheckMate-9K |
Metastatic Prostate Cancer Project The Metastatic Prostate Cancer Project is a nationwide genomic research study for men with advanced and/or metastatic prostate cancer. Patients can join online and participate by sharing their medical information and samples. The goal of the project is to generate a comprehensive database that will be shared with the entire research community to accelerate discoveries in prostate cancer. Learn more about the study |
Menopause and cognitive difficulty study Did you know undergoing surgically or chemically induced menopause could put you at risk for cognitive difficulties? Our study seeks to determine the effectiveness of a stimulant drug called Vyvanse on the cognitive functioning of women who experience executive functioning difficulties following surgically induced menopause. For more information, please contact our team. Learn more about IMPRES |
GENTleMEN Study: Genetic Testing for Men with Metastatic Prostate Cancer The goal of this research study is to determine if online genetic education and testing with online telephone genetic counseling is an acceptable method of delivering genetic testing to men with metastatic prostate cancer.
This study involves undergoing genetic counseling and genetic testing for inherited cancer risk. Learn more about the study |
Athena- rucaparib and novolumab for maintenance in ovarian cancer ATHENA is a study for women who are newly diagnosed with ovarian cancer. ATHENA is looking at whether maintenance therapy with a PARP inhibitor and/or immunotherapy improves outcomes for women who have completed front-line ovarian cancer treatment. Learn more about ATHENA |
Genetic Education for Men (GEM) Study The Genetic Education for Men (GEM) study, is a clinical trial evaluating educational tools for men from families in which a BRCA1/2 gene mutation has been identified. In order to identify untested men from BRCA1/2 families, we are seeking women who have received positive BRCA1/2 test results and have at least one untested male relative. Learn more about the GEM study |
ARIEL4- ovarian cancer ARIEL4 is a treatment study for women with relapsed, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who have a BRCA1 or BRCA2 mutation. ARIEL4 is designed to evaluate rucaparib against standard of care chemotherapy in women who have had at least two prior chemotherapy regimens. Visit the ARIEL4 Study page for more information. More information on ARIEL4 |
TRITON3- prostate cancer The purpose of TRITON3 is to determine how patients with metastatic castration-resistant prostate cancer, and an inherited BRCA1, BRCA2 or ATM gene mutation or tumor genetic deficiency respond to treatment with the PARP inhibitor rucaparib (Rubraca) compared to treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel. More information on TRITON3 |
Metastatic Breast Cancer Project The Metastatic Breast Cancer Project is a patient-partnered initiative that directly engages patients across the US & Canada to transform our understanding of metastatic breast cancer. Patients participate by sharing their medical information, tumor samples, and their voices. There is no cost to participate. A small effort can have a major impact. Learn more about the study |
WISP - Women Choosing Surgical Prevention This study is open to pre-menopausal women between 30-50 with a mutation in BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, BARD1, MSH2, MSH6, MLH1, PMS2 or EPCAM. Women choose to either have their fallopian tubes removed now and their ovaries later or to have their tubes and ovaries removed at the same time. Outcomes are sexual function and quality of life between the women grouped by surgical procedure. Learn more about WISP |
PALB2 Study The PALB2 Study is an international research study looking to recruit women with PALB2 mutations who have been diagnosed with breast cancer. Research shows that PALB2 mutations increase the risk of developing breast cancer; however, it is not clear how to best treat or reduce the risk of breast cancer in women with PALB2 mutations. This research study collects information about breast cancer diagnosis and treatment using short questionnaires in order to learn more about breast cancer among women with a PALB2 mutation. This information will help to determine the best treatment for women with PALB2-associated breast cancer and determine which factors predict survival. Through a better understanding, we can personalize breast cancer treatment to increase survival and determine how to best manage at risk family members to detect cancer early or prevent it. For more information please email [email protected]. |
| FORCE®, FORCE FACING OUR RISK OF CANCER EMPOWERED®, JOINING FORCE AGAINST HEREDITARY CANCER®, PREVIVOR®, and the FORCE Ribbon Design are registered trademarks of FORCE- Facing Our Risk of Cancer Empowered, Inc. in the United States. Unauthorized reproduction or use of FORCE's trademarks is prohibited. |
